DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Eletriptan in migraine.

Author(s): Diener HC

Affiliation(s): Department of Neurology, University of Essen, Hufelandstr. 55, D45122 Essen, Germany. h.diener@uni-essen.de

Publication date & source: 2005-01, Expert Rev Neurother., 5(1):43-53.

Publication type: Evaluation Studies; Review

Migraine is a highly prevalent, chronic and disabling illness in which the gap between practice guideline recommendations and actual clinical practice remains wide. Eletriptan, similar to other triptans, is a potent 5-HT(1B/1D) receptor agonist with a high selectivity for cranial versus coronary artery constriction and favorable pharmacokinetic profile. An extensive program of double-blind, placebo-controlled, head-to-head comparator trials has demonstrated the superior efficacy of eletriptan compared with the combination of ergotamine and caffeine, and selected oral triptans for the acute treatment of migraine. Eletriptans tolerability profile makes it a good choice as a first-line treatment of migraine. An early treatment study suggests that treatment of mild headache is associated with unusually high sustained pain-free rates and a tolerability profile that is equivalent to placebo.

Page last updated: 2006-11-05

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017